Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR

被引:60
|
作者
D'Ambrosio, Roberta [1 ]
Degasperi, Elisabetta [1 ]
Anolli, Maria Paola [1 ]
Fanetti, Ilaria [1 ]
Borghi, Marta [1 ]
Soffredini, Roberta [1 ]
Iavarone, Massimo [1 ]
Tosetti, Giulia [1 ]
Perbellini, Riccardo [1 ]
Sangiovanni, Angelo [1 ]
Sypsa, Vana [2 ]
Lampertico, Pietro [1 ,3 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[2] Natl & Kapodistrian Univ Athens, Dept Hyg Epidemiol & Med Stat, Med Sch, Athens, Greece
[3] Univ Milan, Dept Pathophysiol & Transplantat, CRC AM & A Migliavacca Ctr Liver Dis, Milan, Italy
关键词
Hepatitis C Virus; Cirrhosis; DAA; long-term outcome; SVR; events; HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; ORAL ANTIVIRAL THERAPY; VIRAL ERADICATION; DAA THERAPY; RISK; INFECTION; MORTALITY; FIBROSIS; STAGE;
D O I
10.1016/j.jhep.2021.09.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: As the long-term benefits of a sustained virological response (SVR) in HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we assessed the incidence and predictors of liver-related events (LRE5), non-liver-related events (NLREs) and mortality in DAA-treated patients with cirrhosis. Methods: Consecutive patients with cirrhosis and SVR were enrolled in a longitudinal, single-center study, and divided into 3 cohorts: Cohort A (Child-Pugh A without a previous LRE), Cohort B (Child-Pugh B or Child-Pugh A with prior non-hepatocellular carcinoma [HCC] LRE5), Cohort C (previous HCC). Results: A total of 636 patients with cirrhosis (median 65 years-old, 58% males, 89% Child-Pugh A) were followed for 51 (8-68) months (Cohort A n = 480, Cohort B n = 89, Cohort C n = 67). The 5-year estimated cumulative incidences of LREs were 10.4% in Cohort A vs. 32.0% in Cohort B (HCC 7.7% vs. 19.7%; ascites 1.4% vs. 8.6%; variceal bleeding 1.3% vs. 7.8%; encephalopathy 0 vs. 2.5%) vs. 71% in Cohort C (HCC only) (p <0.0001). The corresponding figures for NLREs were 11.7% in Cohort A vs. 17.9% in Cohort B vs. 17.5% in Cohort C (p = 0.32). The 5-year estimated probabilities of liver-related vs. non-liver-related deaths were 0.5% vs. 4.5% in Cohort A, 16.2% vs. 8.8% in Cohort B and 12.1% vs. 7.7% in Cohort C. The all-cause mortality rate in Cohort A was similar to the rate expected for the general population stratified by age, sex and calendar year according to the Human Mortality Database, while it was significantly higher in Cohort B. Conclusions: Patients with cirrhosis and an SVR on DAAs face risks of liver-related and non-liver-related events and mortality; however, their incidence is strongly influenced by pre-DAA patient history. Lay summary: In this large single-center study enrolling patients with hepatitis C virus (HCV)-related cirrhosis cured by directacting antivirals, pre-treatment liver disease history strongly influenced long-term outcomes. In patients with HCV-related cirrhosis, hepatocellular carcinoma was the most frequent liver-related complication after viral cure. Due to improved longterm outcomes, patients with cirrhosis after HCV cure are exposed to a significant proportion of non-liver-related events. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:302 / 310
页数:10
相关论文
共 50 条
  • [31] Regression of liver stiffness in patients with HCV-related compensated cirrhosis after viral eradication by DAAs
    Vigano, Mauro
    Brancaccio, Giuseppina
    Labanca, Sara
    Cantone, Marco
    Occhipinti, Vincenzo
    Gaeta, Giovanni Battista B.
    Rumi, Maria Grazia
    HEPATOLOGY, 2017, 66 : 836A - 837A
  • [32] Baseline Platelet Is an Independent Predictor for Liver- Related Events after Antiviral Therapy for Compensated HBV-Related Cirrhosis
    Wu, Xiaoning
    Zhou, Jialing
    Wang, Lin
    Sun, Yameng
    Ou, Xiaojuan
    You, Hong
    Jia, Jidong
    Chen, Guofeng
    Xie, Wen
    Ding, Huiguo
    Ma, Hui
    Ma, Anlin
    Xu, Youqing
    HEPATOLOGY, 2018, 68 : 1238A - 1239A
  • [33] Postoperative adverse outcomes after non-hepatic surgery in patients with liver cirrhosis
    Lin, C. S.
    Lin, S. Y.
    Chang, C. C.
    Wang, H. H.
    Liao, C. C.
    Chen, T. L.
    BRITISH JOURNAL OF SURGERY, 2013, 100 (13) : 1784 - 1790
  • [34] IMPACT OF DIABETES ON LIVER RELATED OUTCOMES IN PATIENTS WITH CIRRHOSIS UNDERGOING LIVER TRANSPLANT EVALUATION
    Syed, Taseen
    Trikantzopoulou, Filippa
    Tseng, Michael
    Flynn, Sean
    Healey, Marcus
    Shen, Steve
    McFarland, Kimberly
    Patel, Vaishali
    Matherly, Scott C.
    Lee, Hannah
    Siddiqui, Mohammad S.
    HEPATOLOGY, 2021, 74 : 880A - 881A
  • [35] Incidence and outcomes of thromboembolic and bleeding events in patients with liver cirrhosis in the USA
    Huang, Xiaoquan
    Abougergi, Marwan S.
    Sun, Chenyu
    Murphy, Dermot
    Sondhi, Vikram
    Chen, Bing
    Zheng, Xin
    Chen, Shiyao
    Wang, Yichen
    LIVER INTERNATIONAL, 2023, 43 (02) : 434 - 441
  • [36] The lack of improvement in liver stiffness after SVR in HCV compensated advanced chronic liver disease is associated with the risk of presenting liver related events
    Delgado, M. P.
    Mur, J. I. E.
    Blasco, Victor M. V.
    Ferret, M. B.
    Esteban, R.
    Barciela, M. R.
    Minguez, B.
    Augustin, S.
    Genesca, J.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S542 - S543
  • [37] Association of liver fibrosis progression with non-liver-related mortality in metabolic dysfunction-associated steatotic liver disease
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Koshiyama, Yuichi
    Akita, Tomoyuki
    Kodama, Yuzo
    Tanaka, Junko
    HEPATOLOGY RESEARCH, 2025,
  • [38] Changes in Liver Stiffness and Clinical Outcomes after SVR in Patients with Advanced Fibrosis or Cirrhosis from Hepatitis C Virus
    Kumar, Sonal
    Rosenblatt, Russell E.
    Schweitzer, Arielle
    HEPATOLOGY, 2016, 64 : 1005A - 1005A
  • [39] TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B: LIVER- RELATED CLINICAL OUTCOMES AND SUBGROUP ANALYSIS BY LIVER CIRRHOSIS STATUS
    Kim, Soon Sun
    Seo, Gi Hyeon
    Han, Ji Eun
    Cho, Hyo Jung
    Kim, Eunju
    Yoon, Eileen
    Jang, Eun Sun
    Chang, Jong-In
    Cho, Young Youn
    Lee, Hyung Woong
    Cheong, Jae Youn
    Kim, Hyung Joon
    HEPATOLOGY, 2024, 80 : S168 - S168
  • [40] Influence of DAA treatment in patients with HCV-cirrhosis and esophageal varices on liver transplant free survival and risk of developing hepatocellular carcinoma
    Rodriguez Ferreiro, Noelia
    Florez Diez, Pablo
    Nieto Jara, Alejandro
    Beltran, Victor J.
    Fraile, Miguel
    Alvarez-Navascues, Carmen
    Gonzalez Dieguez, Maria Luisa
    Varela, Maria
    Cadahia-Rodrigo, Valle
    Rodriguez, Manuel
    JOURNAL OF HEPATOLOGY, 2020, 73 : S621 - S621